Analysts Offer Predictions for iBio Q1 Earnings

iBio, Inc. (NYSE:IBIO) – Analysts at Brookline Capital Management issued their Q1 2026 earnings per share estimates for iBio in a research note issued on Wednesday, August 27th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings of ($0.11) per share for the quarter. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Brookline Capital Management also issued estimates for iBio’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.38) EPS.

Separately, Chardan Capital reissued a “buy” rating and set a $5.00 price target on shares of iBio in a research report on Wednesday, June 25th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $5.00.

iBio Stock Performance

IBIO stock opened at $0.83 on Friday. The stock has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $1.82. iBio has a 12-month low of $0.56 and a 12-month high of $6.89. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of iBio by 52.3% during the fourth quarter. Geode Capital Management LLC now owns 83,797 shares of the company’s stock worth $205,000 after purchasing an additional 28,775 shares in the last quarter. Iridian Asset Management LLC CT acquired a new position in shares of iBio during the first quarter worth about $234,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of iBio in the first quarter worth about $224,000. Institutional investors and hedge funds own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.